ME02662B - Niskofrekventna terapija glatiramer acetatom - Google Patents
Niskofrekventna terapija glatiramer acetatomInfo
- Publication number
- ME02662B ME02662B MEP-2017-17A MEP1717A ME02662B ME 02662 B ME02662 B ME 02662B ME P1717 A MEP1717 A ME P1717A ME 02662 B ME02662 B ME 02662B
- Authority
- ME
- Montenegro
- Prior art keywords
- glatiramer acetate
- treatment
- multiple sclerosis
- subcutaneous injections
- reaction
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims 9
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims 9
- 229960003776 glatiramer acetate Drugs 0.000 title claims 9
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000007929 subcutaneous injection Substances 0.000 claims 4
- 238000010254 subcutaneous injection Methods 0.000 claims 4
- 229940126601 medicinal product Drugs 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Claims (4)
1. Glatiramer acetat za upotrebu u režimu od tri potkožne injekcije doze od 40 mg glatiramer acetata na svakih sedam dana, sa najmanje jednim danom između svake dve uzastopne potkožne injekcije, za upotrebu u lečenju pacijenta koji pati od relapsno-remitentne multiple skleroze ili koji je doživeo prvi klinički napad i koji je pod visokim rizikom od razvoja klinički definitivne multiple skleroze, i gde navedeni farmaceutski preparat dalje sadrži manitol.
2. Medikament koji sadrži glatiramer acetat za upotrebu u lečenju pacijenta koji pati od relapsno-remitentne multiple skleroze ili koji je doživeo prvi klinički napad i koji je pod visokim rizikom od razvoja klinički definitivne multiple skleroze, naznačen time što se navedeni medikament primenjuje u režimu od tri potkožne injekcije doze od 40 mg glatiramer acetata na svakih sedam dana, pri čemu je između dve uzastopne potkožne injekcije najmanje jedan dan, i gde navedeni farmaceutski preparat dalje sadrži manitol.
3. Glatiramer acetat za upotrebu prema patentnom zahtevu 1, naznačen time što je podnošljivost tretmana glatiramer acetatom kod pacijenta - čoveka povećana time što je smanjena učestalost trenutne reakcije nakon injekcije ili reakcije na mestu injekcije.
4. Medikament koji sadrži glatiramer acetat za upotrebu prema patentnom zahtevu 2, naznačen time što je podnošljivost tretmana glatiramer acetatom kod pacijenta - čoveka povećana time što je smanjena učestalost trenutne reakcije neposredno nakon injekcije ili reakcije na mestu injekcije. 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US33761210P | 2010-02-11 | 2010-02-11 | |
| EP15171065.4A EP2949335B1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02662B true ME02662B (me) | 2017-06-20 |
Family
ID=43605835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-17A ME02662B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
| MEP-2013-81A ME01536B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2013-81A ME01536B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
Country Status (34)
| Country | Link |
|---|---|
| US (15) | US8399413B2 (me) |
| EP (5) | EP2630962B1 (me) |
| JP (3) | JP6038653B2 (me) |
| KR (4) | KR20140061559A (me) |
| CN (3) | CN105770855A (me) |
| AR (2) | AR077896A1 (me) |
| AT (1) | AT15421U1 (me) |
| AU (1) | AU2010284666B2 (me) |
| BR (1) | BR112012003730A2 (me) |
| CA (2) | CA2760802C (me) |
| CY (2) | CY1114537T1 (me) |
| CZ (2) | CZ30474U1 (me) |
| DE (1) | DE202010018377U1 (me) |
| DK (5) | DK2949335T3 (me) |
| EA (3) | EA019998B9 (me) |
| ES (4) | ES2688873T3 (me) |
| HK (2) | HK1258008A1 (me) |
| HR (4) | HRP20130677T1 (me) |
| HU (2) | HUE031282T2 (me) |
| IL (3) | IL218106A0 (me) |
| LT (3) | LT2630962T (me) |
| ME (2) | ME02662B (me) |
| MX (1) | MX2012002082A (me) |
| NZ (1) | NZ598661A (me) |
| PL (4) | PL2949335T3 (me) |
| PT (4) | PT3199172T (me) |
| RS (2) | RS52885B (me) |
| SG (2) | SG178495A1 (me) |
| SI (4) | SI2949335T1 (me) |
| SK (1) | SK501352015U1 (me) |
| SM (2) | SMT201700057T1 (me) |
| TW (3) | TWI477273B (me) |
| UA (1) | UA103699C2 (me) |
| WO (1) | WO2011022063A1 (me) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| EA019998B9 (ru) * | 2009-08-20 | 2016-01-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| PL2627669T3 (pl) | 2010-10-11 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru |
| EP2765857A4 (en) | 2011-10-10 | 2015-12-09 | Teva Pharma | SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| MX2015008754A (es) * | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (zh) | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| CN114144175A (zh) | 2019-07-22 | 2022-03-04 | 埃科特莱茵药品有限公司 | 治疗多发性硬化症的方法 |
| KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
| KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
| US12357616B2 (en) | 2021-10-11 | 2025-07-15 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
| US11951097B2 (en) * | 2021-10-11 | 2024-04-09 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| ATE55260T1 (de) | 1985-10-11 | 1990-08-15 | Duphar Int Res | Automatische spritze. |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| CA2336238A1 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| HU229719B1 (en) | 1998-09-25 | 2014-05-28 | Yeda Res & Dev | Copolymer-1-delated polipeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| WO2000027417A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| ATE302020T1 (de) | 2000-01-20 | 2005-09-15 | Yeda Res & Dev | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie |
| EP1261361B1 (en) | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| IL153236A0 (en) | 2000-06-05 | 2003-07-06 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| ES2256200T3 (es) | 2000-06-07 | 2006-07-16 | Yeda Research And Development Co., Ltd. | El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato. |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| NZ533327A (en) | 2001-12-04 | 2006-11-30 | Teva Pharma | Processes for the measurement of the potency of glatiramer acetate |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| EP1572271A1 (de) | 2002-11-25 | 2005-09-14 | Tecpharma Licensing AG | Autoinjektor mit rückstellbarer auslösesicherung |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| ZA200505733B (en) | 2003-01-21 | 2006-10-25 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| WO2004091573A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| PL1638589T3 (pl) * | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
| EA200600877A1 (ru) | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| MXPA06011021A (es) * | 2004-03-25 | 2007-04-13 | Johnson & Johnson | Compuestos de imidazol. |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| MXPA06012864A (es) | 2004-05-07 | 2007-07-18 | Peptimmune Inc | Metodo de tratamiento de enfermedades con copolimeros aleatorios. |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| EP2332569A3 (en) * | 2004-06-25 | 2011-09-14 | ID Biomedical Corporation of Quebec | Compositions and methods for treating neurological disorders |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| ES2572811T3 (es) | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
| PT2361924E (pt) | 2004-09-09 | 2014-03-13 | Teva Pharma | Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado |
| AU2005302500B2 (en) | 2004-10-29 | 2008-11-27 | Sandoz Ag | Processes for preparing glatiramer |
| EP1838326A4 (en) | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| PT1848415E (pt) | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| WO2006116602A2 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| CN103316402A (zh) | 2006-06-30 | 2013-09-25 | 艾伯维生物技术有限公司 | 自动注射装置 |
| DE602007003848D1 (de) | 2006-07-05 | 2010-01-28 | Momenta Pharmaceuticals Inc | Verbessertes verfahren zur herstellung von copolymer-1 |
| JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
| EA201070656A1 (ru) | 2007-11-28 | 2010-12-30 | Тева Фармасьютикал Индастриз, Лтд. | Способ задержки начала проявления клинически определенного рассеянного склероза |
| ATE549013T1 (de) | 2009-07-15 | 2012-03-15 | Teva Pharma | Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| EA019998B9 (ru) | 2009-08-20 | 2016-01-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| PL2627669T3 (pl) | 2010-10-11 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru |
| EP2765857A4 (en) | 2011-10-10 | 2015-12-09 | Teva Pharma | SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| MX2015008754A (es) | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| KR20150138240A (ko) | 2013-03-12 | 2015-12-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 리툭시맙 유도 요법과 글라티라머 아세테이트 요법 |
-
2010
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| Ma et al. | Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| RU2760682C2 (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| JP2016204396A5 (me) | ||
| JP2015187125A5 (me) | ||
| WO2009021521A3 (en) | Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression | |
| RU2013123646A (ru) | Комбинированная композиция | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| NZ608292A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| JP2013541583A5 (me) | ||
| JP2007238598A5 (me) | ||
| RU2011139015A (ru) | Вызываемая медикаментозными средствами липоатрофия для косметических целей | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| JP2017508455A5 (me) | ||
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| JP2010519274A5 (me) | ||
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с |